Abstract
ACT-709478 is a selective, orally available T-type calcium channel blocker being studied as a potential new treatment in epilepsy. ACT-709478 had previously been investigated in a single-ascending dose study up to a dose of 400 mg.
Funding Information
  • Actelion Pharmaceuticals (AC-083-102)
  • Idorsia Pharmaceuticals (AC-083-102)

This publication has 33 references indexed in Scilit: